La vendita allo scoperto per Greenwich LifeSciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Greenwich LifeSciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Greenwich LifeSciences (NASDAQ:GLSI) Azioni, Report sulle vendite allo scoperto

Greenwich LifeSciences

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Stifel analyst Tore Svanberg maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Buy and raises the price target from $70 to $82.

News

Price Target

Analyst Ratings

MCHP

Stifel Maintains Buy on Microchip Technology, Raises Price Target to $82

Stifel analyst Tore Svanberg maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Buy and raises the price target from $80 to $115.

CRDO

Stifel Maintains Buy on Credo Technology Group, Raises Price Target to $115

Stifel analyst Tore Svanberg maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $100 to $110.

ALAB

Stifel Maintains Buy on Astera Labs, Raises Price Target to $110

Stifel analyst Tore Svanberg maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and raises the price target from $248 to $270.

Stifel Maintains Buy on Analog Devices, Raises Price Target to $270

<a href="https://x.com/RecursionPharma/status/1946189113138229690" title="https://x.com/RecursionPharma/status/1946189113138229690">https://x.com/RecursionPharma/status/1946189113138229690</a>

Biotech

General

RXRX

Recursion Pharmaceuticals Posts On X "In an industry where over 90% of drug candidates fail, we are relentlessly working to find a better way to discover and develop new medicines. A new feature in @WIRED from @vero_greenwood captures the high-stakes world of drug discovery, highlighting the progress we're making, and the patients who inspire our work. ..."

OpenAI is raking in billions, reshaping industries, and amassing a user base rivaling the world's top tech firms — but it's still not making a dime. <a href="https://www.benzinga.com/topic/artificial-intelligence">If this sounds familiar</a>, it should.
OpenAI co-founder <a href="https://www.benzinga.com/topic/sam-altman">Sam Altman</a> may be running Silicon Valley's next great high-growth, no-profit juggernaut. It&#8217;s a trajectory similar to one his fellow OpenAI co-founder, <a href="https://www.benzinga.com/topic/elon-musk">Elon Musk</a>, used when scaling Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
<h2 class="wp-block-heading">Burning Cash, Building The Future — Just Like Musk Did</h2>
OpenAI's trajectory evokes comparisons to Tesla&#8217;s early years — scaling aggressively, burning cash, yet commanding sky-high valuations on visionary promise. Much like Tesla redefined automotive expectations long before turning a profit, OpenAI is betting that its unmatched consumer traction and AI agent innovation will keep investor belief alive, even as profitability remains distant.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/07/46391210/tesla-and-apple-face-brand-new-wrecking-ball-thanks-to-trump">Tesla And Apple Face Brand-New Wrecking Ball—Thanks To Trump</a>
According to JPMorgan analyst Brenda Duverce, OpenAI is sprinting ahead on revenue, reporting an 82% jump in annualized revenue to $10 billion in the first half of 2025. Indeed, dollars are flying in, but profits remain a distant mirage. Just like Tesla in its earlier years, OpenAI is all about ambition and commanding investor imagination — even if margins are missing in action.
<h2 class="wp-block-heading">The Cult Of ChatGPT Is Real</h2>
With over 800 million users and a valuation north of $300 billion, OpenAI is now the third most valuable private company globally. Consumer subscriptions account for a whopping 75% of its revenue, and ChatGPT ranks as the second-fastest-growing app in digital history. 
OpenAI, which began as a quiet research lab in 2015, has now become a bellwether in the AI industry, according to Duverce.
The company's massive user base and brand advantage could help unlock a total addressable market (TAM) exceeding $700 billion by 2030. But in an ecosystem racing toward commoditization, with Google's Gemini and DeepSeek-R1 hot on its heels, staying in the lead won't come easily.
<h2 class="wp-block-heading">All-In On AI Agents, But No Clear Profit Path</h2>
OpenAI's next bet? AI agents that act autonomously to complete tasks — a possible moonshot to dethrone hardware and ad-tech giants. However, Duverce warns that high inference costs, declining model prices, and a hyper-competitive landscape mean the path to profitability may be years away.
Despite these challenges, OpenAI has raised $63 billion for infrastructure and talent &#8211; a massive war chest that keeps it well ahead of private rivals. 
Still, with no profits expected until 2029 and a valuation at 27x 2025E revenue (triple the Magnificent Seven average), investor expectations are sky-high.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46392190/tesla-identity-crisis-musks-xai-vote-could-rewrite-the-ev-makers-dna">Tesla Identity Crisis: Musk&#8217;s xAI Vote Could Rewrite The EV Maker&#8217;s DNA</a></li>
</ul>
Image: Shutterstock

Long Ideas

Initiation

Tech

Trading Ideas

TSLA

OpenAI's Tesla Playbook: Big Revenue, Zero Profit, All Vision

B. Riley Securities analyst Nick Giles initiates coverage on BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announces Price Target of $7.31.

FUFU

B. Riley Securities Initiates Coverage On BitFuFu with Buy Rating, Announces Price Target of $7.31

In a pivotal moment for the energy sector, Chevron Corporation&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) has won a dispute with Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) over Hess Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HESS#NYSE">HESS</a>) offshore <a href="https://www.benzinga.com/topic/oil">oil assets in Guyana.</a>
Exxon CEO Darren Woods confirmed the latest news in an <a href="https://www.cnbc.com/2025/07/18/chevron-defeats-exxon-in-dispute-over-guyana-oil-assets-clearing-path-for-hess-acquisition.html">interview </a>with CNBC on Friday.
The International Chamber of Commerce&#8217;s (ICC) ruling, which favors Chevron, allows the oil major to complete its <a href="https://www.benzinga.com/government/24/09/41098199/ftc-clears-chevrons-53b-hess-merger-sets-restriction-for-john-hess" target="_blank" rel="noreferrer noopener">$53 billion acquisition of Hess</a>.
&#8220;We disagree with the ICC panel&#8217;s interpretation but respect the arbitration and dispute resolution process. As we&#8217;ve said before, ExxonMobil and CNOOC are aligned that we had a duty to ensure contract terms are always adhered to and not set a bad precedent for ourselves and industry,&#8221; Exxon <a target="_blank" href="https://investor.exxonmobil.com/company-information/press-releases/detail/1190/exxonmobil-responds-to-international-chamber-of-commerce" rel="noreferrer noopener">said</a> in a statement on Friday.
&#8220;Given the significant value we've created in the development of the Guyana resource, we believed we had a clear duty to our investors to consider our preemption rights to protect the value we created through our innovation and hard work at a time when no one knew just how successful this venture would become. We welcome Chevron to the venture and look forward to continued industry-leading performance and value creation in Guyana for all parties involved,&#8221; Exxon added.
Also Read: <a href="https://www.benzinga.com/markets/large-cap/25/07/46372916/chevrons-cost-cuts-diversified-growth-propel-stock" target="_blank" rel="noreferrer noopener">Chevron&#8217;s Cost Cuts, Diversified Growth Propel Stock</a>
Exxon and China's CNOOC had taken their case to the International Chamber of Commerce (ICC), arguing they had a right of first refusal to buy Hess's stake in the Stabroek Block — a major oil project off the coast of Guyana.
Exxon owns 45% of the Stabroek Block and operates it, while CNOOC holds a 25% stake. Both companies opposed Hess's plan to sell itself to Chevron, claiming their contracts gave them the first right of refusal to buy Hess's interest in the block.
Chevron and Hess <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46353438/chevron-hess-arbitration-nears-verdict-as-analyst-sees-limited-downside-big-upside-potential" rel="noreferrer noopener">argued that those rights</a> didn't apply because it was a full company sale, not just a sale of the Guyana assets.
Why It Matters
The disagreement raised doubts about whether Chevron's deal to acquire Hess would go through, putting pressure on Chevron's stock. If Exxon had won the case, the deal could have fallen apart.
The Wall Street Journal <a target="_blank" href="https://www.wsj.com/business/energy-oil/chevron-moves-forward-with-megadeal-for-hess-after-winning-exxon-arbitration-17347067" rel="noreferrer noopener">noted</a> that in Guyana, Exxon runs ships that extract around 650,000 barrels of oil per day. By 2027, oil companies plan to increase that to 1.2 million barrels per day. This would make the small South American nation of 800,000 people one of the top oil producers per person in the world.
On Thursday, the U.S. Federal Trade Commission (FTC) <a href="https://www.ftc.gov/news-events/news/press-releases/2025/01/ftc-approves-final-order-chevron-hess-deal" target="_blank" rel="noreferrer noopener">reversed</a> a previous decision that blocked Hess CEO John B. Hess from joining Chevron's board after its planned acquisition of Hess.
In January 2025, the FTC issued a final order preventing Hess from serving on the board of Chevron.
The agency claimed that Hess had shown support for OPEC's efforts to control oil production and argued that his presence on Chevron's board could lead to the company aligning more closely with OPEC, raising competition concerns.
The decision to overturn the earlier order was passed with a unanimous 3-0 vote.
CVX Price Action: Chevron shares were up 2.97% at $155.87 at the time of publication on Friday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46487918/peter-thiel-backed-hadrian-raises-260-million-to-build-ai-powered-mega-factory-in-arizona" target="_blank" rel="noreferrer noopener">Peter Thiel-Backed Hadrian Raises $260 Million To Build AI-Powered Mega Factory In Arizona</a></li>
</ul>
Photo: Shutterstock

Large Cap

Legal

Movers

HESS

Exxon's Block Fails—Chevron Seals $53 Billion Hess Deal After Ruling

U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
Shares of Independent Bank Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) rose sharply during Friday's session after the company reported second-quarter financial results and beat its adjusted EPS and <a href="https://www.benzinga.com/quote/IBKR">revenue estimates</a>.
Independent Bank reported quarterly earnings of $1.25 per share which beat the analyst consensus estimate of $1.21 per share. The company reported quarterly sales of $181.800 million which beat the analyst consensus estimate of $179.473 million.
Independent Bank shares jumped 6.6% to $69.99 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Blaize Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) shares jumped 50% to $4.58 after announcing a $120 million agreement to deploy its hybrid AI platform in collaboration with Starshine.</li>
<li>Talen Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLN#NASDAQ">TLN</a>) gained 22.4% to $323.13. Morgan Stanley analyst David Arcaro maintained Talen Energy with an Overweight rating and raised the price target from $300 to $330.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) rose 22.4% to $15.13. Mesoblast reported $13.2 million in gross revenue from Ryoncil sales in the first quarter post commercial launch.</li>
<li>loanDepot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) gained 21.4% to $1.9900.</li>
<li>Opendoor Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) rose 21.2% to $2.0000.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) gained 14.7% to $6.09.</li>
<li>So-Young International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) rose 13.9% to $5.70.</li>
<li>CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) gained 13.2% to $62.36.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) rose 11.3% to $46.62 as the company's Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) holdings crossed the $1 billion threshold following its recent pivot to an ETH treasury strategy.</li>
<li>United States Antimony Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAMY#NYSE">UAMY</a>) rose 10.5% to $4.1250.</li>
<li>Invesco Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) gained 10.2% to $19.06.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) climbed 7.7% to $11.76.</li>
<li>Interactive Brokers Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) gained 7.5% to $63.90 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 7.2% to $112.99.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46465973/top-2-defensive-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

$ETH

APLD

BMNR

BZAI

CRSP

EOSE

HOOD

IBKR

INDB

MESO

OPEN

UAMY

Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday

B of A Securities analyst Sara Senatore maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Buy and lowers the price target from $430 to $420.

WING

B of A Securities Maintains Buy on Wingstop, Lowers Price Target to $420

Management

FMAO

F&M Bank Andrew Briggs Steps Down As Chairman Of The Board; Kevin J. Sauder Named Successor

B of A Securities analyst Gregory Francfort maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Buy and lowers the price target from $13 to $11.

B of A Securities Maintains Buy on Wendy's, Lowers Price Target to $11

MetroCity Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCBS#NASDAQ">MCBS</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.63 by 3.17 percent. This is a 1.52 percent decrease over earnings of $0.66 per share from the same period last year. The company reported quarterly sales of $37.911 million which beat the analyst consensus estimate of $36.100 million by 5.02 percent. This is a 4.52 percent increase over sales of $36.271 million the same period last year.

Earnings

Earnings Beats

METROCITY BANKSHARES INC by MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Q2 EPS $0.65 Beats $0.63 Estimate, Sales $37.911M Beat $36.100M Estimate

BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) is preparing to release its quarterly earnings on Monday, 2025-07-21. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect BOK Financial to report an earnings per share (EPS) of $1.99.
The market awaits BOK Financial's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS missed by $0.13, leading to a 1.7% drop in the share price on the subsequent day.
Here's a look at BOK Financial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.99</td>
<td>1.99</td>
<td>1.98</td>
<td>2.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.86</td>
<td>2.12</td>
<td>2.18</td>
<td>2.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1752847331_0.png" alt="eps graph" />
<h3>BOK Financial Share Price Analysis</h3>
Shares of BOK Financial were trading at $103.88 as of July 17. Over the last 52-week period, shares are down 1.97%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BOKF/earnings">To track all earnings releases for BOK Financial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BOKF

Insights Ahead: BOK Financial's Quarterly Earnings

AGNC Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGNC#NASDAQ">AGNC</a>) is set to give its latest quarterly earnings report on Monday, 2025-07-21. Here's what investors need to know before the announcement.
Analysts estimate that AGNC Investment will report an earnings per share (EPS) of $0.41. 
Investors in AGNC Investment are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.04, leading to a 3.55% increase in the share price the following trading session.
Here's a look at AGNC Investment's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.42</td>
<td>0.50</td>
<td>0.54</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.37</td>
<td>0.43</td>
<td>0.53</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>1.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1752847319_0.png" alt="eps graph" />
<h3>Market Performance of AGNC Investment's Stock</h3>
Shares of AGNC Investment were trading at $9.28 as of July 17. Over the last 52-week period, shares are down 9.41%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AGNC/earnings">To track all earnings releases for AGNC Investment visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AGNC

Preview: AGNC Investment's Earnings

Investors with a lot of money to spend have taken a bearish stance on Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with HIMS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 16 uncommon options trades for Hims &amp; Hers Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are calls, for a total amount of $698,237.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $45.0 to $65.0 for Hims &amp; Hers Health over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Hims &amp; Hers Health stands at 1882.0, with a total volume reaching 3,174.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Hims &amp; Hers Health, situated within the strike price corridor from $45.0 to $65.0, throughout the last 30 days.
<h3>Hims &amp; Hers Health Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752847311_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$1.87</td>
<td>$1.71</td>
<td>$1.74</td>
<td>$50.00</td>
<td>$102.4K</td>
<td>5.5K</td>
<td align="right">750</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/25/25</td>
<td>$2.45</td>
<td>$2.33</td>
<td>$2.33</td>
<td>$49.00</td>
<td>$93.7K</td>
<td>967</td>
<td align="right">425</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$2.17</td>
<td>$1.88</td>
<td>$1.88</td>
<td>$49.50</td>
<td>$74.9K</td>
<td>585</td>
<td align="right">432</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$12.75</td>
<td>$12.4</td>
<td>$12.75</td>
<td>$45.00</td>
<td>$63.7K</td>
<td>653</td>
<td align="right">35</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/01/25</td>
<td>$1.38</td>
<td>$1.37</td>
<td>$1.37</td>
<td>$54.00</td>
<td>$57.1K</td>
<td>521</td>
<td align="right">418</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Where Is Hims &amp; Hers Health Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,690,167, the price of HIMS is down by -1.61%, reaching $49.19.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 17 days from now.</li>
</ul>
<h3>What The Experts Say On Hims &amp; Hers Health</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $48.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Hims &amp; Hers Health, targeting a price of $48. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims &amp; Hers Health options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Smart Money Is Betting Big In HIMS Options

Guidance

During Conference Call, SLB CEO Says Expects Flat To Low Single Digit Revenue Growth In Second Half Compared To First Half

WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) is set to give its latest quarterly earnings report on Monday, 2025-07-21. Here's what investors need to know before the announcement.
Analysts estimate that WR Berkley will report an earnings per share (EPS) of $1.04. 
WR Berkley bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 5.23% increase in the share price on the following day.
Here's a look at WR Berkley's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.99</td>
<td>0.95</td>
<td>0.92</td>
<td>0.92</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.01</td>
<td>1.13</td>
<td>0.93</td>
<td>1.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1752847304_0.png" alt="eps graph" />
<h3>Performance of WR Berkley Shares</h3>
Shares of WR Berkley were trading at $68.13 as of July 17. Over the last 52-week period, shares are up 32.11%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WRB/earnings">To track all earnings releases for WR Berkley visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: WR Berkley's Earnings Forecast

Investors with a lot of money to spend have taken a bullish stance on Futu Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FUTU, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 40 uncommon options trades for Futu Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 17%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $227,920, and 37 are calls, for a total amount of $3,161,534.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $200.0 for Futu Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Futu Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Futu Holdings's whale activity within a strike price range from $80.0 to $200.0 in the last 30 days. 
<h3>Futu Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752847305_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$27.35</td>
<td>$24.75</td>
<td>$27.4</td>
<td>$180.00</td>
<td>$822.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$44.95</td>
<td>$43.5</td>
<td>$43.5</td>
<td>$135.00</td>
<td>$217.5K</td>
<td align="right">245</td>
<td align="right">50</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$11.4</td>
<td>$8.45</td>
<td>$11.4</td>
<td>$160.00</td>
<td>$169.8K</td>
<td align="right">130</td>
<td align="right">304</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/01/25</td>
<td>$10.2</td>
<td>$7.25</td>
<td>$9.62</td>
<td>$160.00</td>
<td>$147.3K</td>
<td align="right">130</td>
<td align="right">153</td>
</tr>
<tr>
<td>FUTU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/25/25</td>
<td>$3.55</td>
<td>$2.85</td>
<td>$3.55</td>
<td>$170.00</td>
<td>$145.1K</td>
<td align="right">94</td>
<td align="right">11</td>
</tr>
</tbody>
</table>

<h3>About Futu Holdings</h3>
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
In light of the recent options history for Futu Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Futu Holdings</h3>
<ul>
<li>Currently trading with a volume of 1,785,445, the FUTU's price is up by 9.57%, now at $164.42. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 32 days.</li>
</ul>
<h3>Professional Analyst Ratings for Futu Holdings</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $176.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays has revised its rating downward to Overweight, adjusting the price target to $176. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Futu Holdings options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

FUTU

This Is What Whales Are Betting On Futu Holdings

B of A Securities analyst Sara Senatore maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $203 to $219.

Comments

Greenwich LifeSciences

Vendite allo scoperto

Greenwich LifeSciences (NASDAQ:GLSI) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO